ERBB2 and ovarian carcinoma: Active targeting to ovarian cancer cells using antibodies and receptor ligands such as HER-2 (Cirstoiu-Hapca et al., 2010), OV-TL3 (Storm et al., 1994; Vingerhoeds et al., 1996), folate (Chaudhury et al., 2012; Tong et al., 2014; Werner et al., 2011; Zeng et al., 2013) or luteinizing hormone-releasing hormone analogs (Pu et al., 2014) conjugated to the DDS were used in 30% of the included studies.